Vlad Vitoc, Chief Executive Officer, 10% Owner at MAIA Biotechnology, Inc. (MAIA), bought 72,700 shares at $1.39 ($101K) on 2026-06-01, disclosed to the SEC on 2026-06-02.
CEO Vlad Vitoc executed the largest purchase of his career, buying $100,885.79 worth of shares at $1.39, signaling confidence in the company's recent pivot to a crypto treasury strategy. This trade comes as the stock trades 52% below its 52-week high of $3.19, presenting a potential value entry point.
MAIA is currently trading at $1.53, down 1.92% over the last 90 days and 12.57% over the past year. The stock is trading at a deep discount, sitting 52.04% below its 52-week high of $3.19.
Catalysts include the October 7 headline 'Cancer drug maker takes sudden pivot into crypto' and the September 12 Phase II efficacy win for its NSCLC immunotherapy.
The stock carries a short interest of 5.06% of the float, and the recent pivot to a crypto treasury strategy may introduce regulatory or market volatility risks.
Something here stands out, but not much.
| Filing → |
| MAIA | BUY | 2025-12-04 | $10K | — | Filing → |
| MAIA | BUY | 2025-11-25 | $12K | — | Filing → |
| MAIA | BUY | 2023-05-01 | $10K | — | Filing → |